Autoantibodies to glutamic acid decarboxylase in patients with epilepsy are associated with low cortical GABA levels

50Citations
Citations of this article
45Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Antibodies to glutamic acid decarboxylase (GAD), the major pathway for the synthesis of γ-aminobutyric acid (GABA) in humans, are found at elevated levels in a subgroup of patients with chronic epilepsy. To test whether the antibodies were associated with changes in cortical GABA levels we used magnetic resonance spectroscopy. Four patients with epilepsy and high serum GAD antibody levels (107-6,200 units/ml) and 10 healthy controls were recruited. A 3T GABA-optimized spectrum was obtained from a reproducible voxel in the cortex. Compared to the control group, the patient group had significantly lower GABA concentrations within the cortex. Demonstration of an association between high serum GAD antibodies and low cortical GABA levels in patients with epilepsy suggests that GAD antibodies are, at least, a marker of a specific disease process and support a role for immune-mediated GABAergic dysfunction. © 2010 International League Against Epilepsy.

Cite

CITATION STYLE

APA

Stagg, C. J., Lang, B., Best, J. G., McKnight, K., Cavey, A., Johansen-Berg, H., … Palace, J. (2010). Autoantibodies to glutamic acid decarboxylase in patients with epilepsy are associated with low cortical GABA levels. Epilepsia, 51(9), 1898–1901. https://doi.org/10.1111/j.1528-1167.2010.02644.x

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free